-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia Drug...
-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...
-
Product Insights
NewAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024
Empower your strategies with our Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2024 report and make more profitable business decisions. Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis is a group of autoimmune diseases that cause inflammation and damage to small blood vessels. It is triggered by autoantibodies called ANCAs that target and attack neutrophils, a type of white blood cell. ANCA vasculitis can affect different organs or parts of the body, such as the skin, kidney, or lung. The symptoms,...
-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...
-
Product Insights
NewThrombocytopenia – Drugs In Development, 2024
Empower your strategies with our Thrombocytopenia – Drugs In Development, 2024 report and make more profitable business decisions. Thrombocytopenia refers to a lower than normal platelet count in the blood. Platelets are crucial for blood clotting and preventing bleeding. Various factors can cause thrombocytopenia, including certain medications, infections, autoimmune disorders, or conditions affecting bone marrow function. Symptoms may range from mild bruising and petechiae (small red or purple spots on the skin) to more severe bleeding in the nose, gums, or...
-
Product Insights
NewPrimary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024
Empower your strategies with our Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary Mediastinal B-Cell Lymphoma (PMBCL) is a distinct subtype of non-Hodgkin lymphoma predominantly affecting young adults. Originating in the mediastinum, symptoms include cough, chest pain, and difficulty breathing. Diagnosed through imaging and biopsy, PMBCL resembles large B-cells and expresses markers like CD20 and CD30. Standard treatment involves aggressive chemotherapy, often with rituximab (R-CHOP regimen), and may include radiation. Despite sharing...
-
Product Insights
NewB-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024
Empower your strategies with our B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2024 report and make more profitable business decisions. B-cell acute lymphocytic leukemia (B-Cell ALL), also known as B-cell acute lymphoblastic leukemia, is a type of blood cancer that originates in the bone marrow and affects B-cell lymphocytes, a type of white blood cell. In B-cell ALL, these immature B cells undergo malignant transformation, leading to the rapid production of abnormal lymphoblasts. These abnormal cells...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional ALL therapies was $2.3 billion in 2021. The need for “off-the-shelf” products with lower costs and reduced infrastructure requirements raises the development of allogeneic agents thereby driving the market growth. Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Acute Lymphocytic Leukemia (ALL) –...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...